NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc.(Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on June 23, 2020 issued a composition of matter patent, U.S.PatentNo.10,689,625,with claims directed to the AAV vector used in PR006, Prevails experimental gene therapy program for the treatment of frontotemporal dementia patients withGRNmutations (FTD-GRN). The base patent term extends until October 2038, excluding patent term extensions or coverage in additional related patent filings.
At Prevail, we are working continuously to bring innovative treatments to patients with neurodegenerative diseases, said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. FTD-GRN is a devastating condition, with no disease-modifying therapeutic options available. We are excited about the possibility of making a significant impact with PR006.
In March of this year, Prevail announced an active IND for the Phase 1/2 clinical trial of PR006 for the treatment of FTD-GRN. TheU.S. Food and Drug Administration(FDA) has granted the therapy Fast Track Designation.
PR006 is being developed as a potential one-time gene therapy for FTD-GRN, a progressive neurodegenerative disease caused by mutations in theGRNgene that reduce production of progranulin, a protein critical for lysosomal function, neuronal survival and normal microglial activities. The progranulin deficiency leads to lysosomal dysfunction, ineffective protein degradation and recycling, neuroinflammation, and ultimately neurodegeneration and death, typically within three to ten years of diagnosis.
PR006 is designed to increase progranulin levels in the brains of FTD-GRN patients by delivering a healthy GRN gene using an AAV9 vector.
About Frontotemporal Dementia with GRNMutationsFrontotemporal dementia (FTD) is the second most common cause of dementia in people under the age of 65, after Alzheimers disease. FTD affects 50,000 to 60,000 people in theU.S.and 80,000 to 110,000 individuals in theEuropean Union. FTD-GRN represents 5-10% of all patients withFTD.FTDresults from the progressive degeneration of the frontal and temporal lobes of the brain, which control decision-making, behavior, emotion and language.In FTD-GRN patients, reduced levels of progranulin lead to age-dependent lysosomal dysfunction, neuroinflammation, and neurodegeneration. There are no approved treatments forFTDor FTD-GRN.
AboutPrevail TherapeuticsPrevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. In addition to PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN), the company is developing PR001 for patients with Parkinsons disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease, and PR004 for patients with certain synucleinopathies.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort withThe Silverstein Foundationfor Parkinsons with GBA and OrbiMed, and is headquartered inNew York, NY.
Forward-Looking Statements Related to PrevailStatements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning Prevails ability to develop meaningful therapeutic advances for patients with neurodegenerative diseases. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevails novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevails gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; the fact that gene therapies are novel, complex and difficult to manufacture; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in Prevails filings with theSecurities and Exchange Commission(SEC), including the Risk Factors section of the Companys Quarterly Report on Form 10-Q for the period endedMarch 31, 2020, filed with theSEConMay 14, 2020, and its other documents subsequently filed with or furnished to theSEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:Mary CarmichaelTenBridge Communicationsmary@tenbridgecommunications.com617-413-3543
Investor Contact:investors@prevailtherapeutics.com
The rest is here:
- Study Identifies Breast Cancer Risk and Disease-Causing Mutations in Women Over 65 - Cancer Network - November 28th, 2020
- Scientists say West Africans originally migrated to East Africa - Quartz Africa - November 28th, 2020
- Major new study unveils complexity and vast diversity of Africa's genetic variation - The Conversation CA - November 28th, 2020
- Future Visioning the Role of CRISPR Gene Editing: Navigating Law and Ethics to Regenerate Health and Cure Disease - IPWatchdog.com - November 28th, 2020
- Future Visioning The Role Of CRISPR Gene Editing: Navigating Law And Ethics To Regenerate Health And Cure Disease - Technology - United States -... - November 28th, 2020
- Understanding the immunology of COVID-19 - SelectScience - November 28th, 2020
- Scientists successfully implanted human genes into monkeys to increase their brain mass - Boing Boing - November 28th, 2020
- Thirteen TUM researchers among the most cited worldwide - India Education Diary - November 28th, 2020
- Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results - Business Wire - November 28th, 2020
- Spaceflight does some weird things to astronauts bodies - MIT Technology Review - November 28th, 2020
- Amgen To Present At The Evercore ISI Virtual HealthCONx Conference - GuruFocus.com - November 28th, 2020
- How to use precision medicine to personalize COVID-19 treatment according to the patients genes - TheStreet - September 2nd, 2020
- Meiotic chromosome synapsis depends on multivalent SYCE1-SIX6OS1 interactions that are disrupted in cases of human infertility - Science Advances - September 2nd, 2020
- Thought to Be Extinct, New Guinea's Singing Dogs Found Alive in the Wild - Smithsonian Magazine - September 2nd, 2020
- Humans have had mystery DNA for 300,000 yearsand now we might finally know what it is - SYFY WIRE - August 10th, 2020
- The Secret to a Long, Healthy Life Is in the Genes of the Oldest Humans Alive - Singularity Hub - August 10th, 2020
- LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdatesFDA Clears IND Application for LB-001 for the... - August 10th, 2020
- Research on Tasmanian devil offers new insights into tackling human cancer - National Science Foundation - August 10th, 2020
- Human Genetics Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to 2027 - Owned - August 10th, 2020
- University of Texas researchers find mutation that led to 2015-2016 Zika outbreak - Homeland Preparedness News - August 10th, 2020
- Blood lipid levels may be altered in some autistic people - Spectrum - August 10th, 2020
- NIH taps Dr. Lindsey Criswell as director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases - National Institutes of Health - August 10th, 2020
- 'Hyper urban' coyote genomes are growing apart from their city and rural cousins - Massive Science - August 10th, 2020
- Why scientists are worried about a 'Warp Speed' COVID-19 vaccine - New Haven Register - August 10th, 2020
- Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Its Clinical and Scientific Advisory Boards -... - August 10th, 2020
- Noel Rose, Who Demonstrated Autoimmunity Exists, Dies at 92 - The Scientist - August 10th, 2020
- Invasion of the Body Snatchers: Viruses Can Steal Our Genetic Code to Create New Human-Virus Genes - SciTechDaily - August 10th, 2020
- Why Are Only 10% of People Left-Handed? Here's What Scientists Know So Far - ScienceAlert - August 10th, 2020
- Holder pasteurization of donated human milk is effective in inactivating SARS-CoV-2 - CMAJ - August 10th, 2020
- Dinosaur diagnosed with bone cancer that afflicts humans today - CNN - August 10th, 2020
- LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates - GlobeNewswire - August 10th, 2020
- The Secret to Healthy Longevity Is in the Genes of the Oldest Humans Alive - Singularity Hub - August 10th, 2020
- BU's COVID-19 Testing Passes Its First Test | BU Today - BU Today - August 10th, 2020
- COVID-19 in Africa: Dampening the storm? - Science - August 10th, 2020
- Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and... - August 10th, 2020
- U of T researchers identify molecular switch allowing parasites to survive inside hosts without oxygen - News@UofT - August 9th, 2020
- LUMINEX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - August 8th, 2020
- Gaucher Disease Treatment Market Size, Top Companies, Trends, Growth Factors Details by Regions, Types and Applications - Owned - August 8th, 2020
- How studying genetics and lifestyle can shape a healthier MENA region - The European Sting - August 8th, 2020
- Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group - CDC - August 7th, 2020
- UW researchers devise approach to treat rare, incurable form of blindness - University of Wisconsin-Madison - August 7th, 2020
- Prevail Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Conference - Stockhouse - August 7th, 2020
- human genetics | Description, Chromosomes, & Inheritance ... - August 6th, 2020
- Human Genetics | Pitt Public Health | University of Pittsburgh - August 6th, 2020
- Triplet Therapeutics To Present at Upcoming Events - Business Wire - August 5th, 2020
- 'Hyper urban' coyote genomes are growing apart their from city and rural cousins - Massive Science - August 5th, 2020
- Baylor genomics teams partner to provide COVID-19 testing for Houston area - Baylor College of Medicine News - August 5th, 2020
- Gaucher Disease Treatment Market (Impact of COVID-19) Top Growing Companies: Acetelion Pharmaceutical (J&J Ltd.), Erad Therapeutic Inc., JCR... - August 5th, 2020
- High-fat Diet and Genetics Lead to Anxiety and Depression in Rats - Newswise - August 5th, 2020
- 'Mono' virus turns on cancer-related genes. Here's how. - Live Science - August 4th, 2020
- Human Challenge Trial Neither Essential Nor Ethically Justified at This Time, Says US Expert Anthony Fauci - Yahoo India News - August 4th, 2020
- ICMR to host global web conference on science, ethics of COVID-19 vaccine starting 4.30 pm today - Firstpost - August 4th, 2020
- Faculty/staff honors: Women in engineering network nod, winning magazine article on geologic hazards and refugees and two national genetics society... - July 31st, 2020
- ENCODE3: Interpreting the human and mouse genomes - Science Codex - July 31st, 2020
- Revealing the intrinsic functioning of human and mouse genomes - Tech Explorist - July 31st, 2020
- Maternal Immune Activation Causes Schizophrenia-like Behaviors in the Offspring through Activation of Immune-Inflammatory, Oxidative and Apoptotic... - July 31st, 2020
- Podcast: The ancient war between genes and disease - Genetic Literacy Project - July 31st, 2020
- Pitt's School of Public Health welcomes students with opera about obstetrician who championed hand-washing - TribLIVE - July 31st, 2020
- BNGO Stock Price: BioNano Genomics Inc. retreats, starts week in the red - FXStreet - July 31st, 2020
- A Genetic Mutation Reveals How the SARS-CoV-2 Virus Strikes - Technology Networks - July 31st, 2020
- 88-Year Old Daniel Smith, Son Of Slave, Tells His Story - Moguldom - July 31st, 2020
- 23andMe Releases Devastating Analysis of Trans-Atlantic Slave Trade - Futurism - July 31st, 2020
- MSU researcher earns grant to study effects of droughts - MSUToday - July 31st, 2020
- Massive Growth in Human Genetics Market Breaking new grounds and touch new level in Upcoming Year by QIAGEN, Agilent Technologies, Thermo Fisher... - July 30th, 2020
- CEO of genome analysis firm: We have the data to prove people will take care of themselves - University of Miami - July 30th, 2020
- Researchers from U of T, Harvard study collective human behaviour amid COVID-19 - News@UofT - July 30th, 2020
- Gene mutations discovered as a trigger for male infertility - BioNews - July 29th, 2020
- Cerevel Therapeutics and Cyclica Announce Research Collaboration to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in... - July 29th, 2020
- Relatives of coronavirus may have been in bats for decades - Opelika Auburn News - July 29th, 2020
- Link between platelets and Covid-19 virus? - The New Indian Express - July 29th, 2020
- Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics... - July 29th, 2020
- New 23andMe Study Reveals the Genetic Legacy of Slavery in the Americas - Gizmodo - July 29th, 2020
- The Groundbreaking Scientist Who Risked All in Pursuit of His Beliefs - The New York Times - July 29th, 2020
- 23andMe and GSK Head to Clinical Trials With Cancer Drug - MSN Money - July 29th, 2020
- Human Genetics - David Geffen School of Medicine at UCLA - July 29th, 2020
- Discovering how genetic 'dark matter' plays a role in mental illness is just the tip of the iceberg for human health - The Conversation UK - July 29th, 2020
- The toll of shrinking jaws on human health | Stanford News - Stanford University News - July 28th, 2020
- Global Hereditary Genetic Testing Market (2020 to 2030) - Analysis and Forecast - GlobeNewswire - July 28th, 2020
- Triplet Therapeutics nabs Scholar Rock R&D exec as new CSO - FierceBiotech - July 27th, 2020
- Meet Dr Sarah Gilbert, one of the scientists leading the race to find a coronavirus vaccine - The Indian Express - July 27th, 2020